Sign up to save your podcasts
Or
Share EP66 Everyday Alchemy: Turning Daily Grind into CEO Gold
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
EP66 Everyday Alchemy: Turning Daily Grind into CEO Gold
CEOs are often laser-focused on destinations—quarterly targets, market share goals, and exit strategies. But what if the true measure of leadership lies in valuing the journey as much as the endpoint? This insight comes from a recent conversation with Bob Roda, CEO of Hemasonics, who emphasizes the fulfillment of embracing daily experiences. As someone who regularly engages with CEOs, I've observed a common fixation on end results. However, reflecting on my own career and those of successful leaders, it's clear that real value often emerges from the collective moments of triumph, failure, and growth along the way. This commentary explores the power of balancing destination-driven goals with an appreciation for the journey, offering a fresh perspective on leadership and organizational success that resonates in today's dynamic business landscape.
About our guest:
Robert A. Roda (Bob) joined HemoSonics in February 2020 as the company’s President and CEO, bringing more than 25 years of global experience developing and commercializing innovative diagnostic and medical device products and services.
Most recently, Bob Roda served as President and CEO of Menarini Silicon Biosystems, Inc., a diagnostic and biotech company focused on the use of liquid biopsy and predictive diagnostic tests for the treatment of cancer patients. Prior to that position, he was Vice President and General Manager at Becton Dickinson, where he led the medical and procedural solutions business in the US. From 1998-2012, Bob held positions of increasing responsibility at Johnson & Johnson in both the medical device and diagnostic sectors, with his last role being worldwide VP Marketing in Immunohematology, Donor Screening, and Clinical Laboratories at Ortho Clinical Diagnostics, a J&J company. Bob earned a Bachelor of Arts in Economics from the University of Rhode Island and completed postgraduate coursework at Kellogg Graduate School of Management.
Links from this episode:
HemoSonics website
HemoSonics YouTube channel:
X @HemoSonics
HemoSonics on LinkedIn
Deborah Fell on LinkedIn
Chief Outsiders
View all episodes
By Deborah S. FellCEOs are often laser-focused on destinations—quarterly targets, market share goals, and exit strategies. But what if the true measure of leadership lies in valuing the journey as much as the endpoint? This insight comes from a recent conversation with Bob Roda, CEO of Hemasonics, who emphasizes the fulfillment of embracing daily experiences. As someone who regularly engages with CEOs, I've observed a common fixation on end results. However, reflecting on my own career and those of successful leaders, it's clear that real value often emerges from the collective moments of triumph, failure, and growth along the way. This commentary explores the power of balancing destination-driven goals with an appreciation for the journey, offering a fresh perspective on leadership and organizational success that resonates in today's dynamic business landscape.
About our guest:
Robert A. Roda (Bob) joined HemoSonics in February 2020 as the company’s President and CEO, bringing more than 25 years of global experience developing and commercializing innovative diagnostic and medical device products and services.
Most recently, Bob Roda served as President and CEO of Menarini Silicon Biosystems, Inc., a diagnostic and biotech company focused on the use of liquid biopsy and predictive diagnostic tests for the treatment of cancer patients. Prior to that position, he was Vice President and General Manager at Becton Dickinson, where he led the medical and procedural solutions business in the US. From 1998-2012, Bob held positions of increasing responsibility at Johnson & Johnson in both the medical device and diagnostic sectors, with his last role being worldwide VP Marketing in Immunohematology, Donor Screening, and Clinical Laboratories at Ortho Clinical Diagnostics, a J&J company. Bob earned a Bachelor of Arts in Economics from the University of Rhode Island and completed postgraduate coursework at Kellogg Graduate School of Management.
Links from this episode:
HemoSonics website
HemoSonics YouTube channel:
X @HemoSonics
HemoSonics on LinkedIn
Deborah Fell on LinkedIn
Chief Outsiders